Text Size

A Study of the Safety and Efficacy of Microplasmin to Induce a Posterior Vitreous Detachment (MIVI III)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
ThromboGenics
ClinicalTrials.gov Identifier:
NCT00412958
First received: December 18, 2006
Last updated: January 30, 2013
Last verified: January 2013
History of Changes
Results First Received: December 20, 2012  
Study Type: Interventional
Study Design: Allocation: Randomized;   Endpoint Classification: Safety/Efficacy Study;   Intervention Model: Parallel Assignment;   Masking: Double Blind (Subject, Investigator);   Primary Purpose: Treatment
Condition: Vitrectomy
Interventions: Drug: Ocriplasmin 25µg
Drug: Ocriplasmin 75µg
Drug: Ocriplasmin 125µg
Drug: Placebo

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
The first patient was recruited on 29 Mar 2007 and the last patient completed the study on 02 Oct 2008.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Ocriplasmin 25µg 25µg ocriplasmin intravitreal injection.
Ocriplasmin 75µg 75µg ocriplasmin intravitreal injection.
Ocriplasmin 125µg 125µg ocriplasmin intravitreal injection.
Placebo Intravitreal injection of placebo.

Participant Flow:   Overall Study
    Ocriplasmin 25µg     Ocriplasmin 75µg     Ocriplasmin 125µg     Placebo  
STARTED     29     33     32     31  
COMPLETED     26     29     32     30  
NOT COMPLETED     3     4     0     1  
Withdrawal by Subject                 3                 0                 0                 1  
Adverse Event                 0                 1                 0                 0  
Lost to Follow-up                 0                 1                 0                 0  
Death                 0                 1                 0                 0  
Transport issue                 0                 1                 0                 0  



  Baseline Characteristics
  Hide Baseline Characteristics

Reporting Groups
  Description
Ocriplasmin 25µg 25µg ocriplasmin intravitreal injection
Ocriplasmin 75µg 75µg ocriplasmin intravitreal injection.
Ocriplasmin 125µg 125µg ocriplasmin intravitreal injection.
Placebo Intravitreal injection of placebo.
Total Total of all reporting groups

Baseline Measures
    Ocriplasmin 25µg     Ocriplasmin 75µg     Ocriplasmin 125µg     Placebo     Total  
Number of Participants  
[units: participants]
 		  29     33     32     31     125  
Age  
[units: years]
Mean ± Standard Deviation 		  66.9  ± 8.28     68.8  ± 9.07     66.9  ± 11.40     65.7  ± 11.60     66.1  ± 10.16  
Gender  
[units: participants]
 		         
Female     20     23     20     22     85  
Male     9     10     12     9     40  



  Outcome Measures

1.  Primary:   Proportion of Patients Achieving Total Posterior Vitreous Detachment (PVD) Without Creation of an Anatomical Defect   [ Time Frame: Day 7 ]
  Show Outcome Measure 1


  Serious Adverse Events
  Show Serious Adverse Events


  Other Adverse Events
  Show Other Adverse Events


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
The agreement is:
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
unchecked Other disclosure agreement that restricts the right of the PI to discuss or publish trial results after the trial is completed.


Limitations and Caveats
Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
None  


Results Point of Contact:  
Name/Title: Aniz Girach
Organization: ThromboGenics
phone: +3216751 447
e-mail: aniz.girach@thrombogenics.com


No publications provided


Responsible Party: ThromboGenics
ClinicalTrials.gov Identifier: NCT00412958     History of Changes
Other Study ID Numbers: TG-MV-003
Study First Received: December 18, 2006
Results First Received: December 20, 2012
Last Updated: January 30, 2013
Health Authority: United States: Food and Drug Administration